Inhibrx Inc is a global clinical-stage biotechnology company aiming to discover and develop biologic therapeutic candidates that target life-threatening conditions including oncology and orphan diseases.
Operating in the biomedical and healthcare sector, Inhibrx has a pipeline of four differentiated clinical-stage therapeutic candidates developed for the treatment of Alpha-1 Antitrypsin Deficiency (AATD) and various cancers. Inhibrx Inc. has formed collaborations and partnerships with companies such as 2seventybio and Alpha-1 Foundation with the aim of further extending its research and development.
Monitor the INBX share price by adding it to your eToro watchlist.